It’ll be a little longer before the Food and Drug Administration decides whether it will approve Ofatumumab. That decision is now hoped for by September. Ofatumumab would be the only a monoclonal antibody therapy available as a self-injection. The rest are infusions. Sound like something you’d ask your neuro about?
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.